Form 4: Corcept CEO Sells CORT Shares Under 10b5-1 Plan

Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock on September 2, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Joseph K. Belanoff, the Chief Executive Officer and a Director of Corcept Therapeutics Inc. (CORT), reported the sale of common stock.
• On September 2, 2025, Belanoff disposed of a total of 40,000 shares of CORT common stock.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the Reporting Person on November 26, 2024.
• The shares were sold in two separate transactions: 39,300 shares at a weighted average price of $70.5172 per share, with actual sale prices ranging from $69.97 to $70.96.
• An additional 700 shares were sold at a weighted average price of $71.0107 per share, with actual sale prices ranging from $70.97 to $71.085.
• Following these reported transactions, Belanoff's indirect beneficial ownership through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 stands at 2,821,370 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the transaction was conducted under a pre-arranged 10b5-1 plan, which mitigates concerns that the sale is based on new, adverse non-public information.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the sale was scheduled in advance and not based on new, non-public information, which enhances transparency and reduces concerns about opportunistic insider trading.

Negatives

• Insider selling by a Chief Executive Officer, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence in the company's immediate future, although this is mitigated by the pre-scheduled nature of the plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024, in effect at the time of this transaction.

Industry Context

This insider transaction report is specific to Corcept Therapeutics and its CEO. It does not provide direct information about broader industry trends or competitor activities, but insider trading disclosures are a standard part of market transparency across all industries.

Corporate Governance

Related Party Transactions

• The shares are indirectly held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, indicating a transaction involving a related party (the CEO's trust).

Stakeholder Impact

• Shareholders may scrutinize the sale by the CEO, potentially leading to questions about management's long-term view, although the pre-scheduled nature of the 10b5-1 plan mitigates immediate concerns about the company's prospects.

Key Dates

Recommendation

The sale of shares by the CEO was conducted under a pre-arranged Rule 10b5-1 trading plan. Such plans are typically set up for personal financial planning purposes (e.g., diversification, liquidity) and are not usually indicative of a change in management's outlook on the company's performance. Therefore, this transaction alone does not provide a strong signal to alter an investment position, warranting a 'hold' recommendation.

Keywords

CORT, Corcept Therapeutics, Joseph K. Belanoff, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO